ImmunityBio’s ANKTIVA gains conditional European approval for bladder cancer indication

The European Commission has granted conditional marketing authorisation for immunotherapy ANKTIVA (nogapendekin alfa inbakicept) from ImmunityBio in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.

This makes ANKTIVA plus BCG the first authorised immunotherapy in Europe for this NMIBC indication, providing patients with a therapeutic alternative to radical cystectomy and enabling commercialisation across all 27 EU member states, plus Iceland, Norway, and Liechtenstein. It is now approved in 33 countries spanning four regulatory jurisdictions, establishing a global commercial footprint in under two years from initial FDA approval.

Bladder cancer represents a significant public health burden in the European Union, ranking as the fifth most common cancer overall and the seventh most frequently diagnosed cancer among men.

Non-muscle invasive bladder cancer is the most common form of the disease, which is confined to the bladder lining and has not invaded the underlying muscle layer. For patients whose NMIBC does not respond to BCG therapy, there were no authorised treatment options in the European Union prior to this authorisation. The primary alternative has been radical cystectomy, which carries significant morbidity, affects quality of life, and is not suitable for all patients.

The EC action follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use in December 2025. ImmunityBio will continue to follow up with participants in the study that informed conditional approval and submit long-term safety and efficacy data to the EMA.

Dr Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio, said: “The European Commission’s authorization of ANKTIVA in combination with BCG marks a defining moment for patients with BCG-unresponsive NMIBC CIS across Europe, who until now have had no authorized treatment and faced radical cystectomy as their only alternative. With ANKTIVA now authorized in 33 countries from the United States and United Kingdom to the European Union and Saudi Arabia, we have built the broadest global access platform for an immunotherapy in this indication. With more than 80% of treated patients preserving their bladder through three years of follow-up, ANKTIVA represents a meaningful advance designed to strengthen the immune response and extend the durability of BCG.”

This week ImmunityBio also announced that it will partner with Accord Healthcare to provide access to ANKTIVA to eligible patients in the European Union as well as the establishment of an Irish subsidiary in Dublin.